baseline ischemia and release of VEGF, which then contributes toprogression of RNP and thus worsening of ischemia. Timely, aggressive blockadeof VEGF prevents the worsening of RNP, promotes reperfusion, and eliminates apositive feedback loop. FINANCIAL DISCLOSURE(S): Proprietary or commercialdisclosure may be found after the references.Conclusao: A oclusao da veia inicial e umevento precipitante que causa isquemia de linha de base e lancamento do VEGF,que entao contribui para a progressao da RNP e, portanto, piora da isquemia.Bloqueio oportuno, agressivo de VEGF impede o agravamento da RNP, promove areperfusaoLong-TermIntraocular Pressure Changes in Patients with Neovascular Age-Related MacularDegeneration Treated with RanibizumabMenke M.N. Salam A. Framme C. Wolf S.Ophthalmologica Vol. 229 Nr. 3 Pagina: 168 - 172 Datada publicacao: 01/04/2013Resumo:Background/Aims: Toinvestigate the long-term effects of multiple intravitreal injections (IVTs) ofranibizumab (Lucentis) on intraocular pressure (IOP) in patients withneovascular age-related macular degeneration. Methods: In 320 eyes, IOPmeasurements were performed at baseline prior to injection and compared withIOP measurements of the last visit. Correlations between mean IOP change andtotal number of IVTs, visual acuity or patient age were tested. Results: Themean IOP increase was 0.8 3.1 mm Hg (p < 0.0001). Seven eyes showed finalIOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 14.1 months.No further correlations between IOP change and number of IVTs, visual acuity orpatient age have been found. Conclusions: This study demonstrated astatistically significant IOP increase in patients treated with repeatedinjections of ranibizumab. However, IOP increase required no glaucoma treatmentduring the study. Therefore, repeated injections with ranibizumab can beconsidered safe with regard to long-term IOP changes in patients without ocularhypertension or glaucoma.CONCLUSAO s: Este estudo demonstrou PIOestatisticamente significativo aumentou pacientestratados com injecoes repetidas de ranibizumab. No entanto, aumento da PIO naoexigiu nenhum tratamento de glaucoma durante o estudo. Portanto, repetidasinjecoes com ranibizumab podem ser consideradas seguras no que diz respeito amudancas de longo prazo da PIO empacientes sem hipertensao ocular ou glaucoma.RESPONSEOF RETINAL SENSITIVITY TO RANIBIZUMAB TREATMENT OF MACULAR EDEMA AFTER ACUTEBRANCH RETINAL VEIN OCCLUSION.Mylonas, G.;Sacu, S.; Dunavoelgyi, R.; Matt, G.; Blum, R.; Buehl, W.; Pruente, C.;Schmidt-Erfurth, U.; on behalf of the Macula Study, G.r.oupRetina Vol. 33 Nr. 6 Pagina: 1220 - 1226 Data da publicacao: 01/06/2013Resumo:PURPOSE:: To evaluatemicroperimetry changes in patients with acute macular edema secondary to branchretinal vein occlusion during a follow-up period of 12 months with intravitrealranibizumab treatment (Lucentis; Novartis). METHODS:: Patients with macularedema secondary to branch retinal vein occlusion received an intravitreousinjection of 0.5 mg of ranibizumab (0.05 mL). Best-corrected visual acuity,Spectralis OCT (Heidelberg Engineering), and color fundus photography wereperformed at monthly intervals over a follow-up period of 1 year. Macularfunction was documented by microperimetry (Nidek, MP-1) at baseline, 3, and 12months. RESULTS:: Data of 20 patients without lack of microperimetry resultswere included to the statistical analyses. The size of the area of absolutescotoma was reduced from 16% at baseline to 11.7% at Month 3 and remainedstable in the entire study duration (P > 0.05). Mean differential lightthreshold improved significantly under therapy from 9.47 dB at baseline to12.53 dB at 12 months (P < 0.001). Best-corrected visual acuity correlatedsignificantly with central millimeter thickness and mean retinal sensitivity atbaseline